Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats
Journal of Huntington's Disease · 2024
DOI: 10.3233/jhd-231507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Huntington's Disease, 2024. Verfasst von Russell G Wells und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Whitworth University, Spokane, WA, USA. Hauptthemen laut MEDLINE: Huntington Disease, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Background
Huntington’s disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric dysfunction caused by a mutant huntingtin protein. Compromised metabolic activity resulting from systemic administration of the mitochondrial toxin, 3-nitropropionic acid (3-NP), is known to mimic the pathology of HD and induce HD-like symptoms in rats. N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (PNB-0408), also known as Dihexa, has been shown to have neuroprotective and procognitive properties in animal models of Alzheimer’s and Parkinson’s diseases. Given the mechanism of action and success in other neurodegenerative diseases, we felt it an appropriate compound to investigate further for HD.
Objective
The present study was designed to test if PNB-0408, an angiotensin IV analog, could attenuate 3-NP-induced HD-like symptoms in rats and serve as a potential therapeutic agent.
Methods
Forty male Wistar rats were randomized into three groups consisting of a “vehicle” group, a “3-NP” group, and a “3-NP + PNB-0408” group. PNB-0408 was administered along with chronic exposure to 3-NP. Animal body weight, motor function, and cognitive abilities were measured for five weeks, before euthanasia and histopathological analysis.
Results
Exposure to 3-NP decreased the amount of weight rats gained, impaired spatial learning and memory consolidation, and led to marked motor dysfunction. From our observations and analysis, PNB-0408 did not protect rats from the deficits induced by 3-NP neurotoxicity.
Conclusions
Our findings suggest that PNB-0408 may not be an efficacious treatment strategy for preventing 3-NP-induced HD-like symptoms in a preclinical model. These data highlight the need for further research of this compound in alternate models and/or alternative approaches to managing this disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Whitworth University, Spokane, WA, USA.
- School of Medicine, Oregon Health and Science University, Portland, OR, USA.
- School of Medicine, University of Washington, Seattle, WA, USA.
Zitieren
APA
Wells, R. G., Azzam, A. F., Hiller, A. L., & Sardinia, M. F. (2024). Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Journal of Huntington's Disease. https://doi.org/10.3233/jhd-231507
Vancouver
Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Journal of Huntington's Disease. 2024. doi:10.3233/jhd-231507
BibTeX
@article{Wells2024,
author = {Wells, Russell G and Azzam, Azzam F and Hiller, Amie L and Sardinia, Michael F},
title = {Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats},
journal = {Journal of Huntington's Disease},
year = {2024},
doi = {10.3233/jhd-231507}
}
EUVIMED